TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23800872

Group type: EXPERIMENTAL
Intervention: Isolated venous sinus
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Direct pial venous drainage
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pseudophlebitic pattern
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Venous ectasia
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Brisk venous drainage
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall morbidity rate
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hemorrhage
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: New/worsened NHND
Number of subjects: 41
Study: 21639900

Group type: EXPERIMENTAL
Intervention: Reminder letter alone
Number of subjects: 5523

Group type: EXPERIMENTAL
Intervention: Reminder letter plus reminder call
Number of subjects: 5523

Group type: EXPERIMENTAL
Intervention: Reminder letter plus a second reminder and booklet plus a counselor call
Number of subjects: 5523

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 5523
Study: 19229450

Group type: EXPERIMENTAL
Intervention: Gait trainer exercise
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Walking training over ground
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 56
Study: 16807281

Group type: EXPERIMENTAL
Intervention: Oral HRT (conjugated equine estrogen 0.625 mg/day for 6 months)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Transdermal HRT (17beta‐estradiol gel 0.6 mg/day for 6 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment for 6 months)
Number of subjects: 36
Study: 12891248

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination therapy with fluvastatin (40 mg/day) and fenofibrate (200 mg/day)
Number of subjects: 86
Study: 10848568

Group type: EXPERIMENTAL
Intervention: Speed discrimination task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contrast discrimination task
Number of subjects: 0
Study: 8950722

Group type: EXPERIMENTAL
Intervention: Natural surfactant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 0
Study: 1549214

Group type: EXPERIMENTAL
Intervention: Deprenyl (10 mg/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Deprenyl (withdrawn after 1 month)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 2994795

Group type: EXPERIMENTAL
Intervention: Layered closure
Number of subjects: 507

Group type: COMPARATOR
Intervention: Mass closure
Number of subjects: 507
Study: 31519624

Group type: EXPERIMENTAL
Intervention: Surgery (n=19)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Observation (n=18)
Number of subjects: 86
Study: 29540160

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 probiotic for 4 weeks
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 113
Study: 26983055

Group type: EXPERIMENTAL
Intervention: Indirect moxibustion therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control session (blinded moxibustion smoke and aroma)
Number of subjects: 43
Study: 24565387

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (2 μg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23107851

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 385

Group type: COMPARATOR
Intervention: Lay Foot Manipulation (LFM)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Conventional Care
Number of subjects: 385
Study: 20435194

Group type: EXPERIMENTAL
Intervention: Tolvaptan (oral vasopressin receptor antagonist)
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study: 18076227

Group type: EXPERIMENTAL
Intervention: Programmed method (PC) using speed, agility, quickness (SAQ) conditioning method
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Random method (RC) playing supervised small-sided soccer games
Number of subjects: 46

Group type: COMPARATOR
Intervention: No conditioning (NC)
Number of subjects: 46
Study: 16102553

Group type: EXPERIMENTAL
Intervention: TCu 380A IUD
Number of subjects: 368

Group type: COMPARATOR
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Both interventions (IUD and DMPA)
Number of subjects: 368
Study: 11876714

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis DN-173 010 (three 125 g cups per day of fermented milk)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (fermented milk without bifidobacteria)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis DN-173 010
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 10215097

Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal control participants
Number of subjects: 32
Study: 8525285

Group type: COMPARATOR
Intervention: 150 micrograms/kg followed by placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 400 micrograms/kg with a clearing dose
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 400 micrograms/kg without a clearing dose
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 600 micrograms/kg with a clearing dose
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 600 micrograms/kg without a clearing dose
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 800 micrograms/kg with a clearing dose
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 800 micrograms/kg without a clearing dose
Number of subjects: 75
Study: 2145407

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment for elderly patients with grade III or IV retinopathy, congestive heart failure, or cerebral infarction or hemorrhage.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment for elderly patients with established mild hypertension under 80 years of age.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic antihypertensive treatment for elderly patients over 80 years of age or those with isolated systolic hypertension.
Number of subjects: 0
Study: 394868

Group type: EXPERIMENTAL
Intervention: CAMP chemotherapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: CCNU as a single agent
Number of subjects: 84
Study: 30734357

Group type: EXPERIMENTAL
Intervention: Intraluminal therapy for H. pylori infection (ILTHPI)
Number of subjects: 100
Study: 27837009

Group type: EXPERIMENTAL
Intervention: SafeCare Implementation with Technology‐Assistance (SC‐TA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: SafeCare Implementation as Usual (SC‐IU)
Number of subjects: 31
Study: 25741781

Group type: EXPERIMENTAL
Intervention: upper‐evaluated feedback
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: accurate feedback
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: lower‐evaluated feedback
Number of subjects: 61

Group type: COMPARATOR
Intervention: no feedback
Number of subjects: 61
Study: 24022796

Group type: EXPERIMENTAL
Intervention: Physicians declining patient enrollment
Number of subjects: 3764

Group type: EXPERIMENTAL
Intervention: Reasons for physician refusals
Number of subjects: 3764

Group type: COMPARATOR
Intervention: Experience of research personnel
Number of subjects: 3764

Group type: COMPARATOR
Intervention: Unit type
Number of subjects: 3764

Group type: COMPARATOR
Intervention: Enrollment years
Number of subjects: 3764
Study: 22091267

Group type: EXPERIMENTAL
Intervention: Nasal beclomethasone spray
Number of subjects: 92

Group type: COMPARATOR
Intervention: Amoxicillin and decongestant (control group)
Number of subjects: 92
Study: 19782925

Group type: EXPERIMENTAL
Intervention: Daily walking distance measured by pedometer over one week
Number of subjects: 0
Study: 17095328

Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Number of subjects: 319

Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 319
Study: 14687321

Group type: EXPERIMENTAL
Intervention: Comprehensive review and recommended modification of a patient's medication regimen
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 133
Study: 11576399

Group type: EXPERIMENTAL
Intervention: Highly breathable (HB) diapers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard, nonbreathable disposable diapers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breathable diaper-covered sites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control sites (standard diaper)
Number of subjects: 0
Study: 9401879

Group type: EXPERIMENTAL
Intervention: Continuous Performance Test (CPT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Conners Parent‐Teacher Rating Scale
Number of subjects: 112
Study: 7965276

Group type: EXPERIMENTAL
Intervention: ACE inhibition with quinapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard therapy (diuretic, beta-blocker or both)
Number of subjects: 40
Study: 3632394

Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 31856942

Group type: EXPERIMENTAL
Intervention: Guided self-help intervention (low-intensity psychological intervention based on behavioral activation adapted for autism)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as usual (standard NHS care for depression)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Guided self-help intervention
Number of subjects: 70
Study: 29307330

Group type: EXPERIMENTAL
Intervention: Inulin-type fructan prebiotic (Orafti® Synergy 1; 16 g/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (Glucidex® 29 Premium; 16 g/d)
Number of subjects: 34
Study: 26409473

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 24507631

Group type: EXPERIMENTAL
Intervention: Hypervigilant condition
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 71
Study: 21874605

Group type: EXPERIMENTAL
Intervention: Group mantram intervention
Number of subjects: 66
Study: 20602694

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy adherence
Number of subjects: 386
Study: 17262184

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy without fusion (ACD)
Number of subjects: 551
Study: 15677490

Group type: EXPERIMENTAL
Intervention: AHA Step 2 diet plus endurance exercise
Number of subjects: 62
Study: 11792139

Group type: EXPERIMENTAL
Intervention: Eptifibatide (glycoprotein IIb/IIIa inhibitor)
Number of subjects: 9461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9461

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 9461
Study: 10579750

Group type: EXPERIMENTAL
Intervention: Angiotensin II antagonists at initial doses
Number of subjects: 11281

Group type: EXPERIMENTAL
Intervention: Angiotensin II antagonists at doubled doses
Number of subjects: 11281

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg daily added to initial doses of angiotensin II antagonists
Number of subjects: 11281
Study: 8571305

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t‐PA) antigen
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: fibrin D‐dimer
Number of subjects: 1592

Group type: EXPERIMENTAL
Intervention: von Willebrand factor (vWF)
Number of subjects: 1592
Study: 2346518

Group type: EXPERIMENTAL
Intervention: Long-acting ibuprofen (2,400 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (200 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 465410

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atropine 1%
Number of subjects: 0
Study: 30794229

Group type: EXPERIMENTAL
Intervention: Unsupervised home exercise using a web-based platform (web PT)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Unsupervised home exercise using a printed paper manual (paper PT)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Outpatient physical therapy (outpatient PT)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Unsupervised home exercise (both web PT and paper PT)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Knee Injury and Osteoarthritis Outcome Score (KOOS)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Time back to activities of daily living, time off narcotics
Number of subjects: 290
Study: 28874304

Group type: EXPERIMENTAL
Intervention: Cricoid pressure with ProSeal
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cricoid pressure with Classic
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cricoid pressure with LT
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cricoid pressure with Supreme
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cricoid pressure with air-Q
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cricoid pressure with i-gel
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cricoid pressure with all SGDs
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham pressure with ProSeal
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham pressure with Classic
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham pressure with LT
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham pressure with Supreme
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham pressure with air-Q
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham pressure with i-gel
Number of subjects: 31
Study: 25630627

Group type: EXPERIMENTAL
Intervention: Atorvastatin dentifrice (2% atorvastatin)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 36
Study: 23982340

Group type: EXPERIMENTAL
Intervention: Tacrolimus QD 0.2 mg/kg per day (Arm 2)
Number of subjects: 976

Group type: COMPARATOR
Intervention: Tacrolimus BD 0.2 mg/kg per day (Arm 1)
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Tacrolimus QD 0.3 mg/kg per day (Arm 3)
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Tacrolimus QD 0.2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids (Arm 4)
Number of subjects: 976
Study: 20110160

Group type: EXPERIMENTAL
Intervention: Comprehensive Lifestyle Intervention Program (CLIP)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Simvastatin plus qualitative lifestyle (S+L)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Qualitative lifestyle advice (L)
Number of subjects: 65
Study: 19234513

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (exercise, relaxation, psychoeducation)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 42
Study: 17935515

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 200

Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pimecrolimus cream 1% and Vehicle cream (control)
Number of subjects: 200
Study: 15065957

Group type: EXPERIMENTAL
Intervention: Role induction session at intake
Number of subjects: 267

Group type: COMPARATOR
Intervention: Standard group orientation
Number of subjects: 267
Study: 11468422

Group type: EXPERIMENTAL
Intervention: 1000 mg of SQV SGC twice daily + 100 mg of RTV twice daily (normal breakfast)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 400 mg of SQV HGC twice daily + 400 mg of RTV twice daily (normal breakfast)
Number of subjects: 6
Study: 9725473

Group type: EXPERIMENTAL
Intervention: Parametric method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-parametric method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robust method with asymptotic distribution of the M-estimator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robust method with bootstrap distribution
Number of subjects: 0
Study: 8045143

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 20
Study: 2662837

Group type: EXPERIMENTAL
Intervention: Fenoterol syrup (0.25 mg/kg daily dosage)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fenoterol syrup
Number of subjects: 17
Study: 30861635

Group type: EXPERIMENTAL
Intervention: Cemented reconstruction (CR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Screw-retained reconstruction (SR)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (Cemented reconstruction)
Number of subjects: 44
Study: 28314624

Group type: EXPERIMENTAL
Intervention: SVD summed score
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: White matter hypoattenuation score
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Mean transit time (MTT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Time to maximum flow
Number of subjects: 115
Study: 25428513

Group type: EXPERIMENTAL
Intervention: Road running training program
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10
Study: 23184737

Group type: EXPERIMENTAL
Intervention: Inhaled Fluticasone Furoate (FF) 2000 μg via DISKHALER(®)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Inhaled Fluticasone Propionate (FP) 1000 μg via DISKHALER(®)
Number of subjects: 24
Study: 21564124

Group type: EXPERIMENTAL
Intervention: Evaluative observation by experimenters during the 3-back task
Number of subjects: 32

Group type: COMPARATOR
Intervention: No evaluative observation during the 3-back task
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Evaluative observation during the 3-back task
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Evaluative observation during the 2-back and 1-back tasks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Evaluative observation
Number of subjects: 32
Study: 18474077

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at a maximum dosage of 1500 mg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16814643

Group type: EXPERIMENTAL
Intervention: PG-116800
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 12634020

Group type: EXPERIMENTAL
Intervention: Incentive (financial incentive pay‐out for reaching preset clinical performance targets)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Registry (financial incentives combined with access to a centralized patient registry and intervention system)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (distribution of printed versions of smoking cessation guidelines)
Number of subjects: 40
Study: 10720048

Group type: EXPERIMENTAL
Intervention: Flutamide, testolactone, reduced hydrocortisone dose (average of 8.7 +/- 0.6 mg/m2 x day), and fludrocortisone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydrocortisone and fludrocortisone
Number of subjects: 28
Study: 8874561

Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Epidural bupivacaine (EB)
Number of subjects: 14
Study: 1599348

Group type: EXPERIMENTAL
Intervention: Full program
Number of subjects: 5686

Group type: COMPARATOR
Intervention: Questionnaire only
Number of subjects: 5686
Study: 6141423

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 129
Study: 30909110

Group type: EXPERIMENTAL
Intervention: Low-force mobilization group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-force mobilization group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medium-force mobilization group
Number of subjects: 60
Study: 29124494

Group type: EXPERIMENTAL
Intervention: Three-session telephone-based peer coaching intervention
Number of subjects: 100
Study: 27068880

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored intervention for physical activity and fruit and vegetable consumption, 8 weeks duration
Number of subjects: 790
Study: 25283552

Group type: EXPERIMENTAL
Intervention: Residential Aged Care Integration Program (RACIP) with gerontology nurse specialists (GNSs)
Number of subjects: 2553

Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 2553
Study: 22445512

Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg/d) for 12 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (hypocaloric dietary intervention) for 12 weeks
Number of subjects: 14
Study: 20159906

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 36
Study: 18025538

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Routine cardiac catheterization
Number of subjects: 82
Study: 15632467

Group type: EXPERIMENTAL
Intervention: Ibandronate (bolus intravenous injection)
Number of subjects: 0
Study: 11979209

Group type: EXPERIMENTAL
Intervention: Caffeine reduction education
Number of subjects: 95
Study: 10824073

Group type: EXPERIMENTAL
Intervention: Ondansetron combined with dexamethasone
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Dexamethasone alone
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Ondansetron and dexamethasone in high-risk group
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Dexamethasone alone in high-risk group
Number of subjects: 705
Study: 9064947

Group type: EXPERIMENTAL
Intervention: 24 h NTG-infusion (group A; 0-24 h saline infusion followed by a 24 h NTG-infusion; n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 48 h NTG-infusion (group B; 0-48 h of NTG-infusion; n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline infusion (control for group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NTG-infusion (both groups)
Number of subjects: 32
Study: 1433584

Group type: EXPERIMENTAL
Intervention: Random medical treatment
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Sideline medical treatment
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Unilateral reflux
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Bilateral reflux
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: First-time detected reflux
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Reflux detected more than 1 year before entry
Number of subjects: 401